TCTC Holdings’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $60.2M | Sell |
393,864
-225
| -0.1% | -$34.5K | 1.71% | 14 |
|
|
2025
Q4 | $54.3M | Buy |
394,089
+2,653
| +0.7% | +$347K | 1.62% | 14 |
|
|
2025
Q3 | $50.2M | Sell |
391,436
-200
| -0.1% | -$24.4K | 1.49% | 15 |
|
|
2025
Q2 | $47.4M | Sell |
391,636
-131
| -0% | -$14.8K | 1.52% | 15 |
|
|
2025
Q1 | $43.7M | Sell |
391,767
-2,923
| -0.7% | -$311K | 1.54% | 16 |
|
|
2024
Q4 | $38.4M | Sell |
394,690
-322
| -0.1% | -$34.3K | 1.38% | 19 |
|
|
2024
Q3 | $45.4M | Sell |
395,012
-508
| -0.1% | -$57.6K | 1.54% | 13 |
|
|
2024
Q2 | $42.1M | Sell |
395,520
-2,781
| -0.7% | -$279K | 1.45% | 15 |
|
|
2024
Q1 | $38.5M | Sell |
398,301
-568
| -0.1% | -$58.2K | 1.28% | 17 |
|
|
2023
Q4 | $40.3M | Buy |
398,869
+43
| +0% | +$4.15K | 1.47% | 13 |
|
|
2023
Q3 | $40.6M | Sell |
398,826
-1,300
| -0.3% | -$132K | 1.57% | 11 |
|
|
2023
Q2 | $40.4M | Hold |
400,126
| – | – | 1.61% | 12 |
|
|
2023
Q1 | $36.8M | Buy |
400,126
+543
| +0.1% | +$47.4K | 1.48% | 14 |
|
|
2022
Q4 | $36.3M | Buy |
399,583
+2,150
| +0.5% | +$181K | 1.48% | 15 |
|
|
2022
Q3 | $30.2M | Sell |
397,433
-2,634
| -0.7% | -$218K | 1.31% | 17 |
|
|
2022
Q2 | $33.8M | Sell |
400,067
-2,299
| -0.6% | -$202K | 1.49% | 15 |
|
|
2022
Q1 | $35.3M | Sell |
402,366
-1,266
| -0.3% | -$110K | 1.45% | 16 |
|
|
2021
Q4 | $35.3M | Buy |
403,632
+841
| +0.2% | +$69.8K | 1.51% | 17 |
|
|
2021
Q3 | $32.9M | Sell |
402,791
-3,333
| -0.8% | -$300K | 1.52% | 16 |
|
|
2021
Q2 | $37.1M | Buy |
406,124
+1,821
| +0.5% | +$162K | 1.7% | 15 |
|
|
2021
Q1 | $34.6M | Sell |
404,303
-485
| -0.1% | -$43.5K | 1.64% | 16 |
|
|
2020
Q4 | $38.2M | Sell |
404,788
-875
| -0.2% | -$76.5K | 2.05% | 10 |
|
|
2020
Q3 | $35.3M | Buy |
405,663
+2,473
| +0.6% | +$214K | 2.18% | 8 |
|
|
2020
Q2 | $35.2M | Buy |
+403,190
| New | +$34.8M | 2.09% | 8 |
|
|
2017
Q2 | – | Sell |
-483,764
| Closed | -$32.2M | – | 174 |
|
|
2017
Q1 | $32.2M | Buy |
483,764
+7,868
| +2% | +$524K | 1.97% | 9 |
|
|
2016
Q4 | $31.1M | Buy |
+475,896
| New | +$30.9M | 1.89% | 9 |
|
|
2016
Q3 | – | Sell |
-474,724
| Closed | -$35.1M | – | 175 |
|
|
2016
Q2 | $35.1M | Sell |
474,724
-126
| -0% | -$8.71K | 2.38% | 5 |
|
|
2016
Q1 | $30.8M | Buy |
474,850
+8,426
| +2% | +$573K | 1.94% | 8 |
|
|
2015
Q4 | $36M | Sell |
466,424
-224
| -0% | -$17.8K | 2.16% | 6 |
|
|
2015
Q3 | $38.4M | Buy |
466,648
+1,357
| +0.3% | +$121K | 2.19% | 4 |
|
|
2015
Q2 | $41M | Sell |
465,291
-1,188
| -0.3% | -$109K | 2.35% | 4 |
|
|
2015
Q1 | $41.2M | Sell |
466,479
-5,357
| -1% | -$475K | 2.43% | 3 |
|
|
2014
Q4 | $39.2M | Sell |
471,836
-3,571
| -0.8% | -$296K | 2.37% | 3 |
|
|
2014
Q3 | $40.1M | Buy |
+475,407
| New | +$38.5M | 2.32% | 4 |
|
|
2014
Q2 | – | Sell |
-477,137
| Closed | -$36.4M | – | 167 |
|
|
2014
Q1 | $36.4M | Sell |
477,137
-669
| -0.1% | -$48.7K | 2.09% | 3 |
|
|
2013
Q4 | $34.4M | Buy |
477,806
+111
| +0% | +$7.72K | 1.97% | 4 |
|
|
2013
Q3 | $32.8M | Buy |
477,695
+3,320
| +0.7% | +$220K | 2.11% | 4 |
|
|
2013
Q2 | $30.1M | Buy |
+474,375
| New | +$30.9M | 1.98% | 4 |
|
Other funds holding NVS
TCTC Holdings's NVS Position: Q1 2026 in Review
TCTC Holdings reduced its Novartis (NVS) stake by 0.06% in Q1 2026, selling an estimated $34.5K and leaving 393,864 shares worth $60.2M. The position accounts for 1.71% of the portfolio, ranked #14.
TCTC Holdings first reported a position in NVS in Q2 2013 and has held it in 38 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- TCTC Holdings held 393,864 shares of Novartis worth $60.2M as of Q1 2026.
- TCTC Holdings sold 225 Novartis shares in Q1 2026, an estimated $34.5K.
- Novartis made up 1.71% of TCTC Holdings's portfolio in Q1 2026, its #14 holding.
- TCTC Holdings first reported a position in Novartis in Q2 2013 and has held it in 38 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on TCTC Holdings's 13F filing for Q1 2026, filed 7 May 2026.